Fennec Pharmaceuticals Inc. FENC 深 滬
等待開盤 11-04 09:30:00 美东时间
10.70
+0.160
+1.52%
華盛通- 最 高10.83
- 今 開10.63
- 成交量 13.50万股
- 最 低 10.22
- 昨 收 10.54
- 總市值 3.75亿
- 52周最高 13.25
- 市盈率 靜 --
- 換手率 0.39%
- 52周最低 5.65
- 委 比 -15.61%
- 總股本 3506.72万
- 歷史最高 14.986
- 量 比 0.84
- 振 幅 5.79%
- 歷史最低 3.255
- 每 手 1
- 風險率 1.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FENNEC PHARMACEUTI COM NPV收涨2.93%，成交额190.84万美元
11月3日，FENNEC PHARMACEUTI COM NPV（FENC）收涨2.93%，报10.54美元，成交额190.84万美元，市值3.7亿美元。 行情...
11-03 07:15
FENNEC PHARMACEUTI COM NPV收涨0.69%，成交额117.43万美元
10月27日，FENNEC PHARMACEUTI COM NPV（FENC）收涨0.69%，报10.15美元，成交额117.43万美元，市值3.56亿美元。...
10-27 06:19
FENNEC PHARMACEUTI COM NPV收跌3.57%，成交额130.33万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:22
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
Fennec Pharmaceuticals announced positive results from the STS-J01 clinical trial evaluating PEDMARK® for reducing cisplatin-induced ototoxicity in pediatric and AYA patients in Japan. The study enrolled 33 patients, with 24.0% experiencing ASHA-defined hearing loss, significantly below the historical benchmark of 56.4% (P=0.001). No Grade 3 or 4 hearing loss was observed, and objective tumor responses were seen in 95.8% of evaluable patients. Pr...
09-17 11:30
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $16 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains $16 price target.
09-09 19:18
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $16
Wedbush analyst David Nierengarten maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and raises the price target from $13 to $16.
08-13 00:04
Fennec Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
Fennec Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
08-11 22:51
Fennec Pharmaceuticals Q2 EPS $0.05 Beats $0.02 Estimate, Sales $17.874M Beat $16.095M Estimate
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 150 percent. This is a 145.45 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $17.874 mi...
08-11 19:03
